Table 2.

Histologic assessment of proliferative and apoptotic activity of tumors collected at the end of the efficacy experiment (day 7) and after the regrowth experiment (day 21)

Efficacy experiment (day 7)Regrowth experiment (day 21)
UZLX-STS3UZLX-STS5UZLX-STS7UZLX-STS3UZLX-STS5UZLX-STS7
Proliferative activity
 H&EDoxo↓ 1.21.0↓ 1.1↑ 1.1↓ 1.1n/a
ALGP-doxo↓ 2.9*,#↓3.8*,#↓ 8.2*,#↓ 3.2*,#↓ 3.5*,#n/a
 pHH3Doxo↓ 1.8↓1.1↓ 1.2↓ 1.2↓ 1.2n/a
ALGP-doxo↓ 2.7*↓6.6*,#↓13.6*,#↓ 2.2*,#↓ 3.4*,#n/a
 Ki-67Doxo1.0↑1.11.0↓ 1.11.0n/a
ALGP-doxo↓ 1.6*,#↓1.2*,#↓ 1.7*,#↓ 1.8*,#↓ 1.3*,#n/a
Apoptotic activity
 H&EDoxo↑ 1.3↑ 1.31.01.0↑ 2.0n/a
ALGP-doxo↑ 2.3*,#↑ 5.3*,#↑ 4.2*,#↑ 1.6↑ 3.7*,#n/a
 CC3Doxo1.0↑ 5.5*1.0↑ 1.3↑ 2.0n/a
ALGP-doxo↑ 1.8#↑10.5*,#↑8.3*,#↑ 2.2*,#↑ 3.5*n/a
  • Results are shown as fold changes of the average for each group in comparison with control. Arrows indicate an increase (↑) or decrease (↓) of proliferative or apoptotic activity of treated versus respective control tumors. Statistical significance was calculated using Mann–Whitney U test.

  • Abbreviation: n/a, not assessed (in the ALGP-doxo treated samples of the UZLX-STS7 model collected after the regrowth experiment, tumor tissue was replaced by non-atypical spindle cells in a poorly cellular myxoid background and therefore the assessment could not be performed).

  • *P < 0.05 compared with control.

  • #P < 0.05 compared with doxorubicin.